HeartBeam (NASDAQ: BEAT) Collaborates With Mount Sinai to Advance AI-ECG Algorithm Development

At a glance

Company: HeartBeam, Inc.
Ticker: NASDAQ: BEAT
Announcement: Partnership
Location: New York

Key figures

Issued patents held by HeartBeam: over 20

Products and programs

3D ECG platform
12-lead ECG synthesis software
AI-ECG algorithms

HeartBeam (NASDAQ: BEAT) announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai in New York to accelerate the joint development and validation of next-generation AI-ECG algorithms. The partnership will combine HeartBeam’s patented ECG platform, which captures the heart’s electrical activity from three non-coplanar dimensions, with Mount Sinai’s clinically annotated 12-lead ECG datasets and artificial intelligence expertise to advance AI-driven cardiac monitoring. By leveraging longitudinal, high-fidelity synthesized 12-lead ECG data collected from patients in home settings alongside Mount Sinai’s clinical data resources, the collaboration aims to accelerate the training and validation of AI models designed to support personalized cardiac insights, expand potential clinical indications and enable broader applications in preventive cardiology, chronic disease management and remote patient monitoring.

To view the full press release, visit https://ibn.fm/gKzvQ

About HeartBeam, Inc.

HeartBeam, Inc. is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025(1) . The Company holds over 20 issued patents related to technology enablement.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

In brief

HeartBeam says it has entered a collaboration with the Icahn School of Medicine at Mount Sinai in New York to develop and validate AI-based ECG algorithms. The work will bring together HeartBeam’s three-dimensional ECG platform and Mount Sinai’s clinically annotated 12-lead ECG data and AI expertise. The companies plan to use synthesized ECG data collected longitudinally from patients at home alongside Mount Sinai’s clinical resources to train and assess AI models. HeartBeam says the models are intended to support personalized cardiac insights and could be applied in preventive cardiology, chronic disease management and remote monitoring. The release also notes that HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software received clearance in December 2025.

Key takeaways

HeartBeam and Mount Sinai will jointly develop and validate AI-ECG algorithms.
The collaboration combines HeartBeam’s 3D ECG platform with Mount Sinai’s clinical data and AI expertise.
The work will use synthesized 12-lead ECG data gathered from patients at home alongside Mount Sinai resources.
HeartBeam says its 3D ECG technology and 12-lead synthesis software received FDA clearances in December 2024 and December 2025, respectively.

SEC filings

Earlier from HeartBeam, Inc.

Back to News Center